Value of ultrasound indices for the assessment of rheumatoid arthritis activity and tocilizumab therapy efficiency
https://doi.org/10.14412/1995-4484-2013-1248
Abstract
Objective: to estimate the value of simplified ultrasound (US) indices of synovitis in the most commonly involved joints of the dominant hand, which are studied using the grey scale mode while monitoring the efficiency of tocilizumab (TCZ) therapy in patients with rheumatoid arthritis (RA). Subjects and methods. Forty-six patients with RA confirmed by the 1987 American College of Rheumatology (ACR) criteria who had been ineffectively treated received TCZ infusions for 6 months. The patients were stratified into two groups: 1) 11 patients with early (<2-year) RA (ERA); 2) 35 patients with protracted (>2-year) RA (PRA). Disease activity and therapy efficiency were determined by DAS28-CRP, SDAI, and US study of the dominant hand joints most commonly involved in the pathological process. Results. The evaluation of TCZ therapy from the simplified US indices reflected synovitis regression in the dominant hand joints of patients with ERA. The highly significant correlations between the changes in US parameters and RA activity the indices ^US-wrist/iDAS28-CRP: r = 0.75; p = 0.01; ΔUS-S8/ΔDAS28-CRP and ΔUS-S5/ΔSDAI: r = 0.65; p < 0.05) confirm the validity of the above changes. No reduction in the joint indices was observed in the patients with PRA. Conclusion. The simplified grey-scale US indices of synovitis in the joints of the dominant hand (including one wrist joint) is an accessible noninvasive method for evaluating the efficiency of the therapy performed in patients with ERA.
About the Authors
Rita Aleksandrovna OsipyantsD E Karateev
E Yu Panasyuk
G V Lukina
E N Aleksandrova
S I Glukhova
A V Volkov
E L Nasonov
References
1. <div><p>Насонов Е.Л. Ревматоидный артрит как общемедицинская проблема. Терапевт архив 2004;5:5-7.</p><p>Каратеев Д.Е., Олюнин Ю.А., Лучихина Е.Л. Новые классификационные критерии ревматоидного артрита ACR/EULAR 2010 г. — шаг вперед к ранней диагностике. В кн.: Насонов Е.Л. (ред.). Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. М.: ИМА-ПРЕСС, 2012;46—54.</p><p>Насонов Е.Л. Ревматология: Национальное руководство. М.: ГЭОТАР-Медиа, 2010.</p><p>Чичасова Н.В., Владимиров С.А., Имаметдинова Г.Р. и др. Функциональные исходы ревматоидного артрита при различных способах противовоспалительной терапии. Науч-практич ревматол 2010;2:30-36.</p><p>Scott D.L. The diagnosis and prognosis of early arthritis: rationale for new prognostic criteria. Arthr Rheum 2002;46:286-90.</p><p>Насонов Е.Л. Почему необходима ранняя диагностика и лечение ревматоидного артрита? Рус мед журн 2002;10:1009-14.</p><p>Emery P., Dougados M., Tak P. et al. Treat to Target — tailoring therapy in rheumatoid arthritis. European musculoskeletal review. Rheumatoid arthritis. Touch briefings 2011;1 —7.</p><p>Meenagh G., Filippucci E., Delle Sedie A. et al. Ultrasound imaging for the rheumatologist XIX. Imaging modalities in rheumatoid arthritis. Clin Exp Rheumatol 2009;27:3-6.</p><p>Kamishima T., Tanimura K., Shimizu M. et al. Monitoring antiinterleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger. Skeletal Radiol 2010;doi 10.1007/s00256-010-1064—4.</p><p>Filippucci E., Iagnocco A., Salaffi F. et al. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. Ann Rheum Dis 2006;65:1433-7.</p><p>Iagnocco A., Perella C., Naredo E. et al. Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography. Clin Rheumatol 2008;27:491-6.</p><p>Prevoo M.L.L., van't Hoff M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joints counts. Arthr Rheum 1995;38:44-52.</p><p>Smolen J., Breedveld F., Schiff M. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.</p><p>Wakefield R., Balint P., Szkudlarek M. et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005;32:2485-7.</p><p>Kawashiri S.-Y., Kawakami A., Iwamoto N. et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. J Rheumatol 2010;doi: 10.1093/rheumatology/keq415.</p><p>Backhaus M., Ohrndorf S., Kellner H. et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthr Rheum 2009;61:1194-201.</p><p>Naredo E., Rodriguez M., Campos C. et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment ofjoint inflammation in rheumatoid arthritis. Arthr Rheum 2008;59:515-22.</p><p>Prevoo M.L., van't Hof M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995;38:44-8.</p><p>Scire C.A., Montecucco C., Codullo V. et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology 2009;48:1092-7.</p><p>Hammer H., Kvien T. Comparisons of 7- to 78-joint ultrasonography scores: All different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis. Arthr Res Ther 2011;13:R78;doi:10.1186/ar3341.</p><p>Schmidt W.A. Technology Insight: the role of color and power Doppler ultrasonography in rheumatology. Nat Clin Pract Rheum 2007;3:35-42.</p></div><br />
Review
For citations:
Osipyants R.A., Karateev D.E., Panasyuk E.Yu., Lukina G.V., Aleksandrova E.N., Glukhova S.I., Volkov A.V., Nasonov E.L. Value of ultrasound indices for the assessment of rheumatoid arthritis activity and tocilizumab therapy efficiency. Rheumatology Science and Practice. 2013;51(4):383-386. (In Russ.) https://doi.org/10.14412/1995-4484-2013-1248
Views:
920
Email this article 